Glutamate decarboxylase (GAD) neurons are GABAergic interneurons that synthesize the inhibitory neurotransmitter GABA through decarboxylation of glutamate. These neurons are essential for cortical inhibition, circuit balance, and preventing hyperexcitability. They are critically involved in neurodegenerative diseases characterized by excitation-inhibition imbalance .
- GAD1 (GAD67): Encoded by GAD1 gene, 67 kDa
- GAD2 (GAD65): Encoded by GAD2 gene, 65 kDa
- Co-factors: Pyridoxal phosphate (vitamin B6), PLP
- Substrate: L-glutamate
- Product: GABA + CO₂
- Location: Cytosolic (GAD67), synaptic vesicles (GAD65)
- Regulation: Transcription, alternative splicing
GAD neurons exhibit diverse morphologies:
- Basket cells: Large axonal arbors targeting pyramidal somata
- Somatostatin interneurons: Dendrite-targeting Martinotti cells
- Calretinin interneurons: Late-spiking, diverse targets
- VIP interneurons: Disinhibitory circuits
- Neurogliaform cells: Dense local axon clouds
¶ Marker Genes and Markers
- GAD1: GAD67 mRNA and protein
- GAD2: GAD65 mRNA and protein
- GABA: Neurotransmitter itself
- VGAT (SLC32A1): Vesicular GABA transporter
- Gephyrin: Postsynaptic scaffolding
- Reelin: Some subpopulations
- Feedforward inhibition: From thalamus to cortex
- Feedback inhibition: Recurrent circuit regulation
- Gain control: Modulate firing rates
- Oscillation generation: Gamma, theta rhythms
- Perisomatic inhibition: Control pyramidal neuron output
- Dendritic inhibition: Regulate synaptic integration
- Disinhibition: Enable specific pathways
- Network timing: Coordinate ensemble activity
- GAD neurons regulate experience-dependent plasticity
- Critical for sensory map formation
- Reelin+ interneurons in layer 1
GAD Deficiency:
- Reduced GAD67 in AD hippocampus
- Loss precedes neuron loss
- Contributes to hyperexcitability
Excitation-Inhibition Imbalance:
- Decreased GABA signaling
- Network hyperexcitability
- Seizures in AD patients
Therapeutic Approaches:
- GABAergic drugs have been tried
- Enhancers of GAD function
Basal Ganglia:
- GAD-rich in globus pallidus
- Excessive inhibition in PD
- Contributes to bradykinesia
L-DOPA Effects:
- Alters GAD expression
- Contributes to dyskinesias
GAD Dysfunction:
- Loss of GABAergic neurons
- Failed inhibition
- Seizure generation
Therapeutic:
- GABA agonists
- GAD activation strategies
- Cell transplantation approaches
GABA Deficit:
- Reduced GAD67 in prefrontal cortex
- Cognitive deficits
- Altered gamma oscillations
Molecular Changes:
- Altered GAD1 expression
- Dysregulated GABA synthesis
- Receptor subunit changes
Motor Cortex:
- GAD neuron loss
- Hyperexcitability
- Contributes to degeneration
GAD neurons are vulnerable due to:
- Metabolic demands: High GABA synthesis
- Oxidative stress: Sensitive to ROS
- Excitotoxicity: Glutamate sensitivity
- Calcium dysregulation: High activity
- Cerebral cortex: All layers, ~20-30% of neurons
- Hippocampus: CA1-3, dentate gyrus
- Basal ganglia: Striatum, globus pallidus
- Thalamus: Reticular nucleus
- Cerebellum: Purkinje cells (GAD67)
- Brainstem: Various nuclei
- GABA-A receptor modulators: Benzodiazepines, barbiturates
- GABA-B receptor agonists: Baclofen
- GAD activity enhancers: Pyridoxal phosphate
- GAD1/GAD2 delivery
- VGAT enhancement
- GABA receptor modulation
- GABAergic neuron transplantation
- iPSC-derived interneurons
- Circuit reconstruction